Showing results (321-330 of 383) with videos related to
Sort By:
Pageof 39
Clinical Lung Cancer|January 17, 2004
A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) TrialH Choy, R F DeVore, K R Hande, et al.Alimentary Pharmacology & Therapeutics|May 1, 2014
Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitisD H Johnson, S Khanna, T C Smyrk, et al.The New England Journal of Medicine|November 9, 2000
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology GroupS M Keller, S Adak, H Wagner, et al.Lung Cancer (Amsterdam, Netherlands)|November 21, 2001
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trialH Choy, R F DeVore, K R Hande, et al.British Journal of Cancer|April 5, 2007
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serumS A Belinsky, M J Grimes, E Casas, et al.Lung Cancer (Amsterdam, Netherlands)|December 5, 2006
Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experienceI Gauthier, K Ding, T Winton, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1997
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trailB D Wamil, G B Thurman, H W Sundell, et al.Journal of Medical Genetics|February 7, 2006
Mutations of human TMHS cause recessively inherited non-syndromic hearing lossM I Shabbir, Z M Ahmed, S Y Khan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerJ-C Soria, A Mauguen, M Reck, et al.Oncogene|April 13, 2010
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediatorsS E Wang, Y Yu, T L Criswell, et al.Pageof 39